MOUNTAIN VIEW, Calif., May 15, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that the Company will host its first Analyst Day on Friday, May 17, 2013, in New York, NY, beginning at 8:00am Eastern Time. The event will feature presentations by key opinion leaders in inflammatory bowel disease and renal disease, as well as a corporate update by Thomas J. Schall, PhD, President and Chief Executive Officer of ChemoCentryx.
Topics and guest speakers include:
- CCR9 in Inflammatory Bowel Disease — Satish Keshav, MD, PhD, Consultant Physician & Gastroenterologist and Honorary Senior Lecturer, Translational Gastroenterology Unit, John Radcliffe Hospital, Nuffield Department of Medicine, University of Oxford
- CCR2 in Renal Disease — Richard Glassock, MD, Emeritus Professor of Medicine, David Geffen School of Medicine at the University of California at Los Angeles
The live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. The Company's most advanced drug candidate, vercirnon (also known as Traficet-EN, CCX282 or GSK1605786), a specific CCR9 inhibitor, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development. The Company's lead independent drug candidate, CCX140, a CCR2 inhibitor, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. Other clinical programs include CCX354 (also known as GSK2941266), a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis, CCX168, a C5aR inhibitor in Phase II clinical development for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as CCX872, a CCR2 inhibitor, and CCX507, an inhibitor of CCR9, both of which are in Phase I clinical testing. ChemoCentryx also has several programs in advanced preclinical development.
CCXI - G
CONTACT: ChemoCentryx, Inc. Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer; or Markus J. Cappel, Ph.D. Chief Business Officer 650-210-2900 firstname.lastname@example.org Burns McClellan Caitlyn Murphy (212) 213-0006 email@example.com